Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety of drugs used for the treatment of Crohn's disease.
Pudipeddi A, Kariyawasam V, Haifer C, Baraty B, Paramsothy S, Leong RW. Pudipeddi A, et al. Expert Opin Drug Saf. 2019 May;18(5):357-367. doi: 10.1080/14740338.2019.1612874. Epub 2019 May 6. Expert Opin Drug Saf. 2019. PMID: 31026401 Review.
High prevalence of Crohn disease and ulcerative colitis among older people in Sydney.
Pudipeddi A, Liu J, Kariyawasam V, Borody TJ, Cowlishaw JL, McDonald C, Katelaris P, Chapman G, Corte C, Lemberg DA, Lee CH, Keshava A, Napoli J, Clancy R, Chan W, Paramsothy S, Leong R. Pudipeddi A, et al. Med J Aust. 2021 May;214(8):365-370. doi: 10.5694/mja2.50910. Epub 2021 Jan 27. Med J Aust. 2021. PMID: 33502004
Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
Pudipeddi A, Ko Y, Paramsothy S, Leong RW. Pudipeddi A, et al. Therap Adv Gastroenterol. 2022 Mar 8;15:17562848221080793. doi: 10.1177/17562848221080793. eCollection 2022. Therap Adv Gastroenterol. 2022. PMID: 35282607 Free PMC article.
29 results